Memo Therapeutics advances potravitug as the race for the first BK virus therapy intensifies
Memo Therapeutics’ Phase 2 data show sustained BK polyomavirus reductions and kidney-biopsy improvement, but a missed primary endpoint leaves its pivotal trial carrying the decisive burden.